Neurocrine Biosciences (NASDAQ:NBIX) Given New $166.00 Price Target at Wedbush

Neurocrine Biosciences (NASDAQ:NBIX) had its target price hoisted by stock analysts at Wedbush from $151.00 to $166.00 in a research note issued on Tuesday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Wedbush’s target price indicates a potential upside of 25.30% from the stock’s current price.

Other equities analysts have also recently issued research reports about the company. Wolfe Research began coverage on Neurocrine Biosciences in a report on Tuesday, February 24th. They issued an “outperform” rating and a $160.00 target price for the company. Wall Street Zen cut Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Monday, February 16th. UBS Group decreased their price target on Neurocrine Biosciences from $188.00 to $178.00 and set a “buy” rating for the company in a research note on Friday, January 23rd. Wells Fargo & Company decreased their price target on Neurocrine Biosciences from $180.00 to $175.00 and set an “overweight” rating for the company in a research note on Friday, February 13th. Finally, Mizuho increased their price target on Neurocrine Biosciences from $146.00 to $175.00 and gave the company a “neutral” rating in a research note on Friday, December 12th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $177.00.

Neurocrine Biosciences Stock Up 0.7%

Shares of NBIX stock opened at $132.48 on Tuesday. Neurocrine Biosciences has a twelve month low of $84.23 and a twelve month high of $160.18. The company has a market cap of $13.30 billion, a P/E ratio of 28.43, a P/E/G ratio of 0.69 and a beta of 0.35. The business has a fifty day simple moving average of $131.52 and a 200 day simple moving average of $139.01.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Wednesday, February 11th. The company reported $1.88 earnings per share for the quarter, missing the consensus estimate of $2.36 by ($0.48). Neurocrine Biosciences had a return on equity of 16.48% and a net margin of 16.73%.The business had revenue of $805.50 million for the quarter, compared to the consensus estimate of $804.21 million. During the same quarter in the prior year, the company earned $1.69 earnings per share. Neurocrine Biosciences’s quarterly revenue was up 28.3% compared to the same quarter last year. As a group, equities research analysts anticipate that Neurocrine Biosciences will post 4.28 earnings per share for the current fiscal year.

Insider Buying and Selling at Neurocrine Biosciences

In related news, CEO Kyle Gano sold 36,400 shares of the company’s stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $132.70, for a total transaction of $4,830,280.00. Following the sale, the chief executive officer owned 140,407 shares in the company, valued at $18,632,008.90. This represents a 20.59% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 4.80% of the company’s stock.

Institutional Investors Weigh In On Neurocrine Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in NBIX. USA Financial Formulas bought a new stake in shares of Neurocrine Biosciences during the 4th quarter valued at about $25,000. Geneos Wealth Management Inc. boosted its position in shares of Neurocrine Biosciences by 143.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after purchasing an additional 135 shares in the last quarter. Golden State Wealth Management LLC boosted its position in shares of Neurocrine Biosciences by 120.5% during the 3rd quarter. Golden State Wealth Management LLC now owns 183 shares of the company’s stock valued at $26,000 after purchasing an additional 100 shares in the last quarter. Eastern Bank bought a new stake in shares of Neurocrine Biosciences during the 3rd quarter valued at about $27,000. Finally, DJE Kapital AG bought a new stake in shares of Neurocrine Biosciences during the 4th quarter valued at about $28,000. Institutional investors own 92.59% of the company’s stock.

Key Neurocrine Biosciences News

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Acquisition expands Neurocrine’s commercial footprint by adding VYKAT XR (first/only FDA treatment for hyperphagia in Prader‑Willi Syndrome) and creates a three‑product commercial portfolio alongside INGREZZA® and CRENESSITY®. This supports long‑term revenue diversification. Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio
• Positive Sentiment: Bank of America reiterated a Buy and raised its price target to $199, signaling bullish analyst conviction that the deal meaningfully increases upside despite a near‑term pipeline lull. Neurocrine Biosciences: Vykat XR Acquisition Unlocks Diversified Growth and Upside Potential Despite Near-Term Pipeline Lull
• Positive Sentiment: Needham reaffirmed a Buy with a $185 target, reinforcing that some buy‑side analysts view the acquisition as value‑creating. Needham & Company Reaffirms Buy on Neurocrine
• Neutral Sentiment: Deal mechanics: Neurocrine will pay $53.00 per Soleno share in an all‑cash transaction valued at about $2.9 billion; a conference call was held to discuss terms. These are execution/funding facts investors will monitor. Neurocrine to buy Soleno Therapeutics for $2.9 billion
• Neutral Sentiment: Market validation for the premium: Soleno shares jumped strongly on the deal, highlighting investor appetite for Soleno’s assets and the strategic rationale for Neurocrine. Soleno Therapeutics (SLNO) Soars 32% on $2.9-Billion Merger
• Negative Sentiment: Some analysts remain cautious: BMO kept a Hold and a $140 target, flagging long‑term execution risks for Ingrezza and orphan market rollouts that could offset acquisition benefits. Balanced View on Neurocrine Biosciences: Favorable Soleno Acquisition Prospects Offset by Long-Term Ingrezza and Orphan Market Execution Risks
• Negative Sentiment: Short‑term headwinds: Neurocrine’s stock initially dropped on the announcement (acquirer sell‑off is common after M&A news) as investors digest the $2.9B cash outlay, integration risk and near‑term pipeline cadence. This Pharma Stock Is Surging 40%. Neurocrine Is Buying It in $2.9 Billion Deal.
• Negative Sentiment: M&A call/transcript and analyst commentary highlight execution and integration questions investors should track (commercial roll‑out for VYKAT XR, orphan market uptake, and funding). Neurocrine Biosciences, Inc. (NBIX) M&A Call Transcript

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.